Buy Kaletra

Kaletra

What is Kaletra?

Kaletra is a prescription antiretroviral medication used in the United Kingdom for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. It contains two active ingredients:

• Lopinavir - a protease inhibitor that blocks an enzyme the virus needs to replicate.
• Ritonavir - a low-dose protease inhibitor that mainly works by inhibiting the CYP3A4 enzyme, thereby boosting the level of lopinavir in the bloodstream.

Kaletra is supplied as a bottle of tablets; a typical pack contains 60 tablets. In the UK it is a prescription-only medicine (POM) authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). The product is marketed by AbbVie.

How Kaletra Works in the Body

Lopinavir binds to the active site of the HIV-1 protease enzyme, preventing the cleavage of viral poly-protein precursors. This stops the formation of mature, infectious virus particles.

Ritonavir, at the low doses used in Kaletra, does not primarily contribute antiviral activity. Instead, it inhibits the cytochrome P450 3A4 (CYP3A4) pathway that would normally metabolise lopinavir. By slowing lopinavir’s breakdown, ritonavir raises and prolongs lopinavir concentrations, allowing the once-daily dose to remain effective.

The combined effect leads to a rapid decline in HIV viral load, giving the immune system a chance to recover (increase in CD4⁺ T-cell counts).

Conditions Treated by Kaletra

• HIV-1 infection in adults and adolescents (aged 12 years and older) when used in combination with other antiretroviral agents as recommended by UK HIV treatment guidelines (British HIV Association - BHIVA).

Kaletra is not indicated as a stand-alone regimen; it must be part of a highly active antiretroviral therapy (HAART) regimen that typically includes two nucleoside reverse-transcriptase inhibitors (NRTIs).

Evidence-Based Off-Label Uses

COVID-19 (SARS-CoV-2) infection - Early in the pandemic, Kaletra was investigated as a potential treatment for COVID-19 because of its protease-inhibiting properties. Large, well-controlled randomised trials (e.g., RECOVERY, WHO Solidarity) have shown no clinically meaningful benefit. Consequently, UK guidelines do not recommend Kaletra for COVID-19 outside of a clinical trial.

Disclaimer: Off-label use of any medication must be undertaken only under the direct supervision of a qualified healthcare professional, with a clear assessment of potential risks and benefits.

Who Should (Not) Use Kaletra?

Ideal Candidates

• Adults or adolescents with confirmed HIV-1 infection who require a protease-inhibitor-based regimen.
• Patients whose HIV genotype indicates susceptibility to lopinavir/ritonavir.

Absolute Contraindications

• Known hypersensitivity to lopinavir, ritonavir, or any tablet excipients.
• Severe hepatic impairment (Child-Pugh C) - the drug’s metabolism is heavily liver-dependent.

Relative Contraindications / Cautions

• Moderate hepatic dysfunction (Child-Pugh A-B) - dose adjustment may be needed.
• Pregnancy & lactation - Kaletra is classified as Pregnancy Category C in the UK. Use only if the expected benefit outweighs potential risk to the fetus. Ritonavir is excreted in breast-milk; breastfeeding while on Kaletra is generally discouraged.
• Renal impairment - not a major elimination pathway, but monitor for drug-related toxicities.
• Concomitant use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) - may reduce lopinavir levels and compromise efficacy.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal: diarrhoea, nausea, abdominal discomfort (often mild and transient).
• Metabolic: increase in triglycerides, cholesterol, and blood glucose levels.
• Taste disturbances: metallic or unpleasant taste, especially with the oral solution (tablet form less common).

Serious Adverse Events

• Hepatotoxicity: elevated liver enzymes, rare cases of severe hepatitis; monitor liver function regularly.
• Pancreatitis: persistent abdominal pain and raised lipase/amylase.
• Cardiac conduction abnormalities: rare reports of QT-interval prolongation; caution in patients with existing cardiac disease or electrolyte imbalances.
• Severe skin reactions: Stevens-Johnson syndrome or toxic epidermal necrolysis (very rare).

Drug Interactions

Major Interactions

• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, certain HIV integrase inhibitors) can markedly increase lopinavir concentrations → risk of toxicity. Dose reduction or alternative therapy may be required.
• CYP3A4 inducers (e.g., rifampicin, St. John’s wort, carbamazepine) can substantially lower lopinavir levels → risk of virological failure.

Moderate Interactions

• Statins (especially simvastatin, lovastatin) - increased risk of myopathy; prefer pravastatin or pravastatin at the lowest effective dose.
• Anticoagulants (warfarin) - ritonavir may enhance anticoagulant effect; monitor INR closely.
• Oral contraceptives - ritonavir can increase plasma concentrations of estrogen and progestin; additional contraceptive methods are advisable.

Food and Lifestyle Interactions

• Food: Take Kaletra tablets with a moderate-fat meal to improve lopinavir absorption. Skipping meals may reduce drug exposure.
• Alcohol: No direct interaction, but excessive alcohol can worsen liver toxicity.
• Driving/Machinery: No specific impairment, but severe gastrointestinal side effects might affect concentration.

General Advice: Always provide your clinician with a complete list of prescription medicines, over-the-counter drugs, herbal products, and supplements before starting Kaletra.

How to Take Kaletra

• Standard adult regimen: Two tablets twice daily (morning and evening) taken with food.
• Packaging note: Each bottle contains 60 tablets, enough for a 15-day supply at the standard dosing schedule.
• Special populations:
• Hepatic impairment - dosing may be reduced; follow prescriber instructions.
• Elderly - start with the standard regimen but monitor for toxicity more closely.
• Pediatrics (≥12 years) - dosage is weight-based; the prescriber will select the appropriate tablet strength.

Administration tips

• Swallow tablets whole; do not crush or chew.
• If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose. Do not double-dose.
• Store the bottle at room temperature (20-25 °C), protected from moisture and direct sunlight.

Overdose

• Symptoms may include nausea, vomiting, diarrhoea, and severe abdominal pain.
• Seek emergency medical care immediately; supportive care is the mainstay of treatment. No specific antidote exists.

Discontinuation

• Kaletra should not be stopped abruptly without medical guidance, as sudden withdrawal can lead to a rapid rise in viral load. A structured treatment change or tapering plan may be recommended by the HIV specialist.

Monitoring and Follow-Up

• HIV viral load - baseline, then every 3-6 months to assess treatment success.
• CD4⁺ T-cell count - baseline and periodic monitoring to gauge immune recovery.
• Liver function tests (ALT, AST, bilirubin) - at baseline, then every 1-3 months, especially in patients with pre-existing liver disease.
• Lipid profile & fasting glucose - monitor quarterly, as protease inhibitors can cause dyslipidaemia and hyperglycaemia.
• Renal function - routine labs; dose adjustments are rarely needed but advisable in severe renal disease.

Storage and Handling

• Keep the bottle tightly closed and store at 20-25 °C.
• Protect from excessive heat, humidity, and direct sunlight.
• Do not use tablets that are discoloured, broken, or past the expiry date printed on the label.
• Keep out of reach of children; consider a child- resistant cap.

Medication-Specific Glossary

Protease inhibitor

A class of antiretroviral drugs that block the HIV protease enzyme, preventing the virus from maturing into an infectious form.

Pharmacokinetic booster

A substance (ritonavir in Kaletra) that inhibits drug-metabolising enzymes to increase the plasma concentration of another medication (lopinavir).

Viral load

The quantity of HIV RNA copies per millilitre of blood; a primary marker used to assess treatment effectiveness.

Medical Disclaimer

This article provides educational information about Kaletra and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.